RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Xgene Pharma, a Shanghai start-up, raised $20 million in series B financing round led by Ping An Ventures. Xgene’s lead product, a combination of naproxen and pregabalin (Lyrica®) for chronic pain, is in Phase II trials in the US. Founded in 2016, Xgene Pharma develops small-molecule drugs for chronic pain, infectious diseases and tumors. Also participating in the funding were Zhongtai Investment, a subsidiary of Indonesia’s Sinar Mas Group, and existing investors Morningside Venture Capital and TF Capital.
Source: China Biotoday
